MedTrace Logo

Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca

NCT01074814 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-09-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the response rate, that is the % of patients with non-progression of their metastatic breast cancer after 4 months on treatment that was selected by molecular testing and proteomics.

Conditions

Interventions

DRUG

Approved therapy will be assigned based on molecular profile and RPMA results

treatment will be assigned based on IHC\< FISH, DNA microarray and RPMA results

Sponsors & Collaborators

  • Side-Out Foundation

    collaborator OTHER

  • Translational Drug Development

    lead OTHER

Principal Investigators

  • Gayle Jameson, RNMSNACNP-BC · Scottsdale Healthcare

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01074814 on ClinicalTrials.gov